The Drug Discovery Process

Slides:



Advertisements
Similar presentations
Dr Claes Wilhelmsson Executive Director Research & Development Innovation and the life sciences.
Advertisements

Drug design and testing,. Drug Names Chemical name- describes its molecular structure and distinguishes it from other drugs.
For Bite of Science (October 9, 2012)
Regulatory Framework Leigh Shaw, Director.
Drug Research and Development (R&D) Karol Godwin DVM.
Challenges in new drug discovery in South Asia
The Statisticians Role in Pharmaceutical Development
1 Statistical Work Experiences in a Major Pharmaceutical Company Qiming Liao, Ph.D Hui Zhi, Ph.D GlaxoSmithKline Pharmaceuticals, R&D Nov 4, 2011.
Key Questions WHO WHAT WHERE WHEN WHY HOW Pfizer Inc
S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.
Translational Medicine Turning Basic Research into Medicines and Treatments.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Stefan Franzén Introduction to clinical trials.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Drug Discovery Process
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.
REGISTRATION OF MEDICINES & PROGRESS WITH RESTRUCTURING THE MCC 1.
Stages of drug development
Drug discovery and development
The Drug Development Process
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Obtaining and Negotiatiing a Position in Industry/Biotech Roy G. Smith Ph.D. Director, Huffington Center on Aging Professor, Department of Molecular and.
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Chemical and Biological Defense Program (CBDP): Capabilities for Countering the Threat MG Donna Barbisch, USA Director, CBRN Integration April 26, 2005.
1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.
Stefan Franzén Introduction to clinical trials.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,
OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.
1 Intellectual Property in the Innovative Pharmaceutical Industry *** June 12, 2006 Gregg C. Benson Assistant General Counsel – Intellectual Property 1.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
CHEE DRUG PRODUCT DEVELOPMENT u Drug ä agent intended for use in the diagnosis, mitigation, treatment, cure, or prevention of disease in man or animals.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Concepts and Applications of Pharmacokinetics
Developing medicines for the future and why it is challenging Angela Milne.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Intellectual Property Rights and Pharmaceutical Industry
Privacy Symposium / HIPAA Summit
FDA Office of Orphan Products Development
C LINICAL R ESEARCH. CONTENTS Drug Development Process Pre – Clinical Studies Clinical Trials Phase I Phase II Phase III Phase IV 2.
“Journey of a Drug” From Test Tube TO Prescribing Physician.
European Patients’ Academy on Therapeutic Innovation Non-clinical development.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
E-Clinical
Pharmacodynamics Department Of Pharmacology. Tolerance: Decreased response to a drug following repeated administration though the dose is constant. Acute.
Shows tendency for mergers. These big companies may be shrinking – much research is now outsourced to low cost countries like Latvia, India, China and.
독성학 박 대 훈 한약재산업학과
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Big Discoveries, Small.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
Section I General principle of Pharmacology. Where can you get information about general principle of Pharmacology?  Text books:  Katzung, Basic and.
The process of drug development. Drug development 0,8 – 1 mld. USD.
FDA DRUG APPROVAL FDA’s Lengthy Drug Approval Process in Twelve Steps Overview of the FDA Drug Approval Process Drug Developed June 13, 2016 | Emilia Varrone.
Pharmacology Science that studies interactions of drugs with organism on different levels (subcellular, cellular, organ, systemic) Studies: - relationship.
Drug Development Process Stages involved in Regulating Drugs
The Stages of a Clinical Trial
Drug Development Overview CET Square 1 Program November 4, 2014
New Drug Application(NDA) Vs Abbreviated new drug application (ANDA)
Drug Discovery &Development
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
Prof. Dr. Basavaraj K. Nanjwade
Clinical Drug Development
An Introduction to Medicinal Chemistry 3/e
Drug Development Stages
CTD Module 4: Non-Clinical Studies SPC Relevant Scientific information
Insight into the Pharmaceutical Industry
Drug Design and Drug Discovery
Considerations for Successful Biopharmaceutical Product Development: Discovery to Proof of Concept -A Panel Discussion Stanley C. McDermott, PharmD, MS,
Presentation transcript:

The Drug Discovery Process Target selection & validation Discovery Development Target -receptor; -ion channel; -transporter; -enzyme; - signalling molecule Studies of Disease Mechanisms Drug Candidate safety testing Human Studies Phases I,II, III Lead Search -Develop assays (use of automation) -Chemical diversity -Highly iterative process The Drug Discovery Process Molecular Studies Drug Approval and Registration Lead optimization -selectivity -efficacy in animal models -tolerability: AEs mechanism- based or structure-based? -pharmacokinetics -highly iterative process Animal Studies - relevant species - transgenic KO/KI mice - conditional KOs - agonists/antagonists - antibodies - antisense - RNAi

Target Selection & Validation Define the unmet medical need (disease) Understand the molecular mechanism of the disease Identify a therapeutic target in that pathway (e.g gene, key enzyme, receptor, ion-channel, nuclear receptor) Demonstrate that target is relevant to disease mechanism using genetics, animal models, lead compounds, antibodies, RNAi, etc. Here is what we are trying to achieve (refer to slide). Note that you can comment on: We conduct basic animal health research in RY, but our animal health care products are marketed by Merial, a joint venture between Merck and Rhone- Poulenc (note that RP is now known as Aventis (RP merged with Hoechst). Outcomes research is when we attempt to prove that our compounds not only cause important chemical effects in the body (such as reduced blood pressure or reduced cholesterol), but that these effects lead to reduced morbidity and mortality over time. The Zocor 4S study is an example. The research budget for MRL is $2.4 billion this year.

Discovery Develop an assay to evaluate activity of compounds on the target - in vitro (e.g. enzyme assay) - in vivo (animal model or pharmacodynamic assay) Identify a lead compound screen collection of compounds (“compound library”) compound from published literature screen Natural Products structure-based design (“rational drug design”) Optimize to give a “proof-of-concept” molecule—one that shows efficacy in an animal disease model Optimize to give drug-like properties—pharmacokinetics, metabolism, off-target activities Safety assessment, Preclinical Candidate!!! Here is what we are trying to achieve (refer to slide). Note that you can comment on: We conduct basic animal health research in RY, but our animal health care products are marketed by Merial, a joint venture between Merck and Rhone- Poulenc (note that RP is now known as Aventis (RP merged with Hoechst). Outcomes research is when we attempt to prove that our compounds not only cause important chemical effects in the body (such as reduced blood pressure or reduced cholesterol), but that these effects lead to reduced morbidity and mortality over time. The Zocor 4S study is an example. The research budget for MRL is $2.4 billion this year.

Development Pre-Clinical Clinical Process R&D Chem Eng. R&D Manufacturing Bio Process R&D Safety Assessment Toxicology Drug Metabolism (ADME) Pharmacology Pharmaceutical R&D Formulation Regulatory Affairs Project Planning & Management Marketing Clinical Investigator & patient Clinical Pharmacology Clinical Research Statistics & Epidemiology Data Coordination Research Information Systems Information Services

IND Clinical Trials Phase I Phase II Phase III Investigational 20 - 100 healthy volunteers take drug for about one month Remote data entry Product Profile Marketing SOI Information Learned 1. Absorption and metabolism 2. Effects on organs and tissue 3. Side effects as dosage is increased Investigational New Drug application IND Clinical Trials Phase II Several hundred health-impaired patients Treatment Group Control Group Information Learned 1. Effectiveness in treating disease 2. Short-term side effects in health -impaired patients 3. Dose range Phase III Hundreds or thousands of health-impaired patients Information Learned 1. Benefit/risk relationship of drug 2. Less common and longer term side effects 3. Labeling information Compassionate Use

Worldwide Marketing Authorization (WMA) in other countries Advisory Committee Clinical Trials Continued Regulatory Review Team APPROVAL PROCESS (Ex. FDA) Reviews, comments, and discussions Submit to Regulatory Agencies New Drug Application (NDA) APPROVAL Drug Co./Regulatory liaison activities Worldwide Marketing Authorization (WMA) in other countries

Drug Discovery—Convergence of Disciplines Combinatorial Chemistry Synthetic Physical Patent Law Information Technology Modelling Novel Molecule Intellectual Property Structural Activity Pharmacokinetic Properties In Vivo activity Safety Design Pharmaco- dynamics Physiology Biochemistry DMPK Enzymology Immunology Pharmacology Physiology Physiology Safety Assessment Metabolism Pharmacology Pathology Behavior Physiology Physiology